Clariane shares, among the strongest gainers in the SBF 120, rise 1.75%
The provider of medicalised nursing homes and home care services extends its recovery at midday, in a well-oriented Parisian market. The stock moves clearly away from its recent lows, while remaining below its long-term averages.
A rebound that reclaims the MA20 and places the stock in the upper part of the SBF 120
Clariane shares rise 1.75% to €3.50, among the strongest gainers in the SBF 120, while the index gains 0.7% and the CAC 40 advances 0.73%. The weekly gain reaches 5.55%, bringing the price 5.68% back above its MA20, at €3.31.
The rebound remains limited by the MA50, at €3.55, which the price has not yet reclaimed (a gap of 1.46%), and by the nearby resistance at €3.51. The MACD, back in positive territory, supports this recovery.
A decline of 12.33% over three months remains: the price is still 9.38% below the MA200, at €3.86. Emeis, a comparable stock in the sector, gains 1.03% and has still fallen by more than 23% over the quarter.
Third-quarter revenue up 4.9% on an organic basis
The stock had already jumped on 29 October, following the publication on 28 October of third-quarter revenue of €1,352 million, up 4.9% on an organic basis, driven by improved occupancy in medicalised nursing homes.
At the time of this publication, the group confirmed all its targets, including an average annual organic revenue growth of around 5% and a 7% to 9% annual increase in pro forma EBITDA before IFRS 16 over 2025-2028.
Risks cited include macroeconomic uncertainties linked to the Middle East and reliance on a gradual improvement in occupancy rates. On 22 October, Clariane had also taken over seven training institutes of the Croix-Saint-Simon, representing around 800 students, through its corporate university. The €3.51 level, the nearest resistance, will be the one to watch for the continuation of the rebound.
